Pregnancy Outcomes of Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Among Patients With Autoimmune Diseases: A Scoping Review
Authors' conclusion
Our scoping review of evidence to date on the perinatal use of tsDMARDs reveal small sample sizes and a limited number of studies, all largely descriptive in nature.
Study context
- Population
- Patients with autoimmune diseases (ulcerative colitis, RA, psoriasis) exposed to targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) in pregnancy, before conception (fathers) or in utero8 studies included
- Outcome
- Evidence on pregnancy outcomes of tsDMARDs
Methodological detailsEmbase, MEDLINE and CENTRAL searched in November 2023
- Embase, MEDLINE and CENTRAL searched in November 2023
Main finding
As reported in the abstract
- Studies included of 6,712 screened
- eight
- Sample sizes (pregnancies or offspring)
- 1 to 116
- Studies on tofacitinib
- six
- Studies on baricitinib
- one
- Studies on upadacitinib
- one
- Outcomes extracted: fetal/neonatal; fetal/neonatal-maternal; maternal
- 19; six; three
- Studies reporting congenital anomaly
- n = 4
- Studies reporting preterm birth
- n = 4
- Studies reporting spontaneous abortion
- n = 4
- Studies reporting delivery via Cesarean section
- one
Original publication
Pregnancy Outcomes of Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Among Patients With Autoimmune Diseases: A Scoping Review. Arthritis Care Res (Hoboken). Published 24 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →